NCT03720262 (PHaLIR) is a Phase 2, PHASE3 clinical trial of Mesh reinforcement in Loop Ileostomy, sponsored by Karolinska Institutet.

Who is sponsoring NCT03720262?

NCT03720262 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT03720262?

Interventions in NCT03720262: Mesh reinforcement, No reinforcement.

What condition does NCT03720262 study?

NCT03720262 studies Loop Ileostomy.

Is NCT03720262 still recruiting?

NCT03720262 is currently recruiting now. Last updated 19 August 2025.

Last reviewed 2025-08-19 · How we verify

NCT03720262: PHaLIR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Hernia After Loop Ileostomy Reversal

Recruiting now Phase 2, PHASE3 Last updated 19 August 2025

What this trial tests

Phase 2, PHASE3 trial testing Mesh reinforcement in Loop Ileostomy in 208 participants. Currently enrolling.

Timeline

1 March 2018

Primary endpoint
31 December 2026

31 December 2029

Quick facts

Lead sponsor	Karolinska Institutet
Phase	Phase 2, PHASE3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	208
Start date	1 March 2018
Primary completion	31 December 2026
Estimated completion	31 December 2029
Sites	4 locations across Sweden

Drugs / interventions tested

Mesh reinforcement
No reinforcement

Conditions studied

Loop Ileostomy — all drugs for Loop Ileostomy →

Sponsor

Karolinska Institutet

Who can join

Adults 18 to 90, any sex, with Loop Ileostomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PHaLIR is a prospective, double-blinded randomized study in which patients planned for stoma reversal after rectal cancer surgery are randomized between retro muscular mesh Ultrapro Advanced or standard treatment without mesh.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

PHaLIR: prevent hernia after loop ileostomy reversal-a study protocol for a randomized controlled multicenter study.
Eklöv K, Bringman S, Löfgren J, Nygren J, et al · · 2023 · PMID 37684648 · DOI 10.1186/s13063-023-07430-w

Verify or expand the search:

Other trials of Mesh reinforcement

Trials testing the same drug.

NCT04134455 — The Mesh-RTL Project, for Prevention of Incisional Hernia · NA · completed

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03720262 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 19 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03720262.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing